SynthAsia

GSK Q3 2026 Revenue Rises 5% to GBP 8.9 Billion as Specialty Medicines Surge 15%, Vaccines Stumble on Weak Shingrix China Demand
Company

GSK Q3 2026 Revenue Rises 5% to GBP 8.9 Billion as Specialty Medicines Surge 15%, Vaccines Stumble on Weak Shingrix China Demand

GlaxoSmithKline Plc (GSK; NYSE: GSK) reported Q3 2026 revenues of GBP 8.89 billion (USD 11.91 billion), up 5% at constant exchange rates (CER), driven by double-digit growth in specialty medicines,…

Hengrui Pharma Q3 2026 Revenue Jumps 20.55% and Non-Recurring Net Profit Nearly Doubles – Innovative Drugs Now Drive 65% of Drug Sales as Generics Shrink

Hengrui Pharma Q3 2026 Revenue Jumps 20.55% and Non-Recurring Net Profit Nearly Doubles – Innovative Drugs Now Drive 65% of Drug Sales as Generics Shrink

Kelun Pharma's Sac-TMT Wins CDE Review Acceptance for Seventh Indication – First-Line Non-Squamous NSCLC Combo with MSD's KEYTRUDA

Kelun Pharma’s Sac-TMT Wins CDE Review Acceptance for Seventh Indication – First-Line Non-Squamous NSCLC Combo with MSD’s KEYTRUDA

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

SynthAsia and Shanghai General Hospital Partner to Advance Diabetic Retinopathy Research